In vitro and in vivo synergistic activity of antibiotic combinations against colistin-resistant pseudomonas aeruginosa: a study from a tertiary care hospital in Bangladesh

Sefat-E-Rabbi Eva; Ritu Saha; Shaharat Farha Tangim; Shatabdi Mallick; S. M. Shamsuzzaman

doi:10.18203/2320-6012.ijrms20261667

Authors

Sefat-E-Rabbi Eva Department of Microbiology, Sir Salimullah Medical College, Dhaka, Bangladesh
Ritu Saha Department of Microbiology, Ad-Din Momin Medical College, Dhaka, Bangladesh
Shaharat Farha Tangim Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh
Shatabdi Mallick Department of Microbiology, Khulna, Bangladesh
S. M. Shamsuzzaman Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20261667

Keywords:

Colistin resistance, Pseudomonas aeruginosa, MIC, Murine model

Abstract

Background: The emergence of colistin-resistant Pseudomonas aeruginosa poses a serious therapeutic challenge, particularly in low- and middle-income countries where treatment options are limited. Combination therapy is increasingly explored to improve clinical outcomes, but in vivo validation still remains insufficient.

Methods: A cross-sectional experimental study was conducted at a tertiary-care hospital in Bangladesh (2019). Clinical isolates of P. aeruginosa were identified and tested for antimicrobial susceptibility following CLSI guidelines. Colistin resistance was detected by agar dilution MIC testing and further confirmed by PCR. Molecular detection of colistin resistance–associated genes (PMR A, PMR B, PMR C, PHO P, PHO Q and mcr-1-5) was done by PCR. In vitro synergy of colistin–imipenem and colistin–amikacin combinations were evaluated by MIC reduction and fractional inhibitory concentration index (FICI). A murine infection model was used to assess the therapeutic efficacy.

Results: Among the 63 isolates of P. aeruginosa, 12 (19.5%) were identified as colistin-resistant. Multidrug resistance was observed among all the isolates, with high-level colistin MICs (≥4 µg/ml). Chromosomally mediated resistance genes (PMR and PHO systems) were only detected instead of any plasmid-mediated mcr genes. In vitro synergy testing demonstrated 100% synergistic activity for colistin–imipenem (FICI ≤0.5), whereas colistin–amikacin showed predominantly indifferent effects. In vivo, the combination of colistin–imipenem led to complete bacterial clearance from the mice with 100% survival, whereas the colistin–amikacin combination resulted in 100% mortality, similar to untreated controls.

Conclusions: The Colistin–imipenem combination demonstrates strong in vitro synergy and superior in vivo efficacy against colistin-resistant P. aeruginosa, highlighting its potential as a practical therapeutic option specially in resource-limited settings.

References

Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013;39(4):682-92.

Ramírez-Estrada S, Borgatta B, Rello J. Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist. 2016;9:7-18.

Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, van Duin D. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria. Antimicrob Agents Chemother. 2017;61(6):e02671-16.

Ali J, Rafiq QA, Ratcliffe E. Antimicrobial resistance mechanisms and potential synthetic treatments. Future Sci OA. 2018;4(4):FSO290.

Gandra S, Alvarez-Uria G, Turner P, Joshi J, Limmathurotsakul D, Van Doorn HR. Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries. Clin Microbiol Rev. 2020;33(3):e00048-19.

Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):441-51.

Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;40(9):1333-41.

Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601.

Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2010;13(5):132-8.

Tamayo R, Choudhury B, Septer A, Merighi M, Carlson R, Gunn JS. Identification of cptA, a PmrA-regulated locus required for phosphoethanolamine modification of the Salmonella enterica serovar typhimurium lipopolysaccharide core. J Bacteriol. 2005;187(10):3391-9.

Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643.

Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8.

Abd El-Baky RM, Masoud SM, Mohamed DS, Waly NG, Shafik EA, Mohareb DA, et al. Prevalence and Some Possible Mechanisms of Colistin Resistance Among Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa. Infect Drug Resist. 2020;13:323-32.

Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, et al. Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. Pharmacotherapy. 2015;35(1):34-42.

Daoud Z, Mansour N, Masri K. Synergistic Combination of Carbapenems and Colistin against P. aeruginosa and A. baumannii. Open J Med Microbiol. 2013;3(4):253-8.

Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56(5):2683-90.

Sarkar S, Heise MT. Mouse Models as Resources for Studying Infectious Diseases. Clin Ther. 2019;41(10):1912-22.

CLSI. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute. 2019. Available at: https://scholar.google.com/scholar_lookup?title=Performance%20standards%20for%20antimicrobial%20susceptibility%20testing.%20CLSI%20supplement%20M100&publication_year=2019. Accessed on 11 March 2026.

Haeili M, Javani A, Moradi J, Jafari Z, Feizabadi MM, Babaei E. MgrB Alterations Mediate Colistin Resistance in Klebsiella pneumoniae Isolates from Iran. Front Microbiol. 2017;8:2470.

Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Eurosurveillance. 2018;23(6):17-672.

Almira EC, Panayotova N, Farmerie WG. Capillary DNA sequencing: maximizing the sequence output. J Biomol Tech JBT. 2003;14(4):270-7.

Doern CD. When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing. J Clin Microbiol. 2014;52(12):4124-8.

Toledo PV, Tuon FF, Bail L, Manente F, Arruda P, Aranha-Junior AA. Experimental model for treatment of extended-spectrum β-lactamase–producing Klebsiella pneumoniae. Arq Bras Cir Dig. 2014;27(3):168-171.

Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, García-Curiel A, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother. 2000;45(4):493-501.

Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017;49(5):526-35.